Only in Titles

           Search results for: Recombinant Human LHRH Proteins    

paperclip

#   // Save this To Up


2493 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#30991063   // Save this To Up

Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide.

Conventional drug delivery systems have many limitations including cytotoxicity and affecting non-specific cells. Cell-targeting peptides (CTPs) as a potential class of targeting moiety have some advantages over previous targeting moieties such as monoclonal antibodies, offer additional benefits to design systems using CTPs. Here we have engineered listeriolysin O (LLO) pore-forming toxin by adding a luteinizing hormone-releasing hormone (LHRH) targeting peptide to its N-terminus. Two versions of the toxin, with and without targeting peptide, were sub-cloned into a bacterial expression plasmid. BL21 DE3 cells were used for induction of expression and recombinant proteins were purified using nickel-immobilized metal affinity chromatography column. In order to treat MDA-MB-231 and SKOV3 cell lines as LHRH receptor positive and negative cells, two mentioned LLO toxins were used to evaluate their cytotoxicity and specificity. Our results reveal that the IC of LLO toxin on MDA-MB-231 and SKOV3 cells was 0.32 and 0.41 μg/ml respectively. Furthermore, IC of fusion LHRH-LLO toxin on the cells was 0.88 and 19.55 μg/ml. Cytotoxicity of engineered LHRH-LLO toxin on negative cells was significantly 48-fold lower than wild-type LLO toxin. But this difference has been lowered to only 2.7-fold less cytotoxicity in positive cells. To the best of our knowledge, the current work as the first study regarding engineered toxin revealed that CDC family members could be used to target the specific cell-type.

2436 related Products with: Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide.

Abeta (1 40 42) | 4D8 | o Abeta (1-40 42) | 4D8 | o AccuzolTM Total RNA Extra Mouse Anti-E. coli Labile Mouse Anti-Clostridium di Rabbit Anti-LHRH GNRH Pol Rabbit Anti-LHRH GNRH Pol Clostridum difficile toxi MOUSE ANTI HUMAN LUTEINIZ Rabbit Anti-Clostridium b Rabbit Anti-Cholera Toxin Rabbit Anti-LHRH GNRH Pol

Related Pathways

paperclip

#30935302   // Save this To Up

Comparison of luteal phase ovulation induction and ultra-short gonadotropin-releasing hormone agonist protocols in older patients undergoing in vitro fertilization.

Many undergoing in vitro fertilization-embryo transfer (IVF-ET) procedures treatments have been tried for older infertile patients, but still can not reverse the aging effect on oocyte, and infertility treatment is expensive, even for people in developed countries. The study aimed to compare outcomes following the application of luteal phase ovulation induction (LPOI) and ultra-short gonadotropin-releasing hormone agonist (GnRH-a) protocols in patients aged more than 40 years undergoing IVF-ET and to examine the effectiveness and feasibility of LPOI. A total of 266 IVF-ET cycles in 155 patients aged 40 years and over were retrospectively analyzed. Of these patients, 105 underwent the ultra-short GnRH-a protocol (GnRH-a group) and 50 underwent LPOI (LPOI group). Various clinical outcomes were compared between these two groups using either t-tests or the chi-square test. The study showed patients in the LPOI group required a higher dosage of human menopausal gonadotropin and a lower dosage of recombinant follicle stimulating hormone than those in the GnRH-a group. Furthermore, though the total dosage of gonadotropin was higher in the LPOI, its cost was lower. Finally, fertilization rates were higher and high-quality embryo rates were lower in the LPOI group, and the live birth rate of LPOI group is higher than (GnRH-a group) . These between-group differences were all significant (P < 0.05). Compared with the ultra-short GnRH-a protocol, LPOI may enable higher 2-pronuclear embryo fertilization rates and lower gonadotropin costs to be achieved, indicating that LPOI might be an ideal choice for older patients undergoing IVF-ET.

2329 related Products with: Comparison of luteal phase ovulation induction and ultra-short gonadotropin-releasing hormone agonist protocols in older patients undergoing in vitro fertilization.

Bovine Mullerian Inhibiti Syringe pump can be contr Glucagon ELISA KIT, Rat G Human integrin aVb3, affi MarkerGeneTM in vivo lacZ Inhibitory Mouse Monoclon Anti beta3 AR Human, Poly GLP 1 ELISA Kit, Rat Gluc Cultrex In Vitro Angiogen Inhibitory Mouse Monoclon Leptin ELISA Kit, Rat Lep Resorufin Oleate, Fluorog

Related Pathways

paperclip

#30910145   // Save this To Up

Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.

To evaluate the effect of the GnRH antagonist on gonadotropin ovulation induction in women with PCOS.

2126 related Products with: Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.

Ovarian cancer test tissu Ovary disease spectrum (o Syringe pump can be contr Ovarian cancer tissue arr Ovarian cancer tissue arr Ovary cancer test tissue Ovary cancer and adjacent Glucagon ELISA KIT, Rat G Interleukins Recombinant Ovary serous papillary ad Bovine Mullerian Inhibiti Goat Anti-Human Wiskott-A

Related Pathways

paperclip

#30794953   // Save this To Up

The impact of HCG in IVF Treatment: Does it depend on age or on protocol?

to evaluate the effect of the addition of low dose human chorionic gonadotropin (hCG) to human menopausal gonadotropin (HMG) throughout the early follicular phase in controlled ovarian stimulation (COS) conducted with two difference regimens. Gonadotropin-releasing hormone (GnRH) antagonist and short GnRH-agonist protocol were applied in two in vitro fertilization (IVF) clinics.

1935 related Products with: The impact of HCG in IVF Treatment: Does it depend on age or on protocol?

Rabbit Anti-FGF3 Oncogene FDA Standard Frozen Tissu Thermal Shaker with cooli FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ tumor tiss FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ cancer tis Multiple organs tumor and Mouse Protein Z-Dependent

Related Pathways

paperclip

#30609935   // Save this To Up

Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.

Diminished ovarian reserve (DOR) remains one of the greatest obstacles affecting the chance of a successful live birth after fertility treatment. The present study was set to investigate whether using a "dual trigger" consisted of human chorionic gonadotropin (hCG) plus gonadotropin releasing hormone agonist (GnRH-a) for final oocyte maturation could improve the IVF cycle outcomes for patients with diminished ovarian reserve.

1196 related Products with: Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.

Free Beta-Subunit of Huma Human Chorionic Gonadotro Chorionic Gonadotropin (C Human Chorionic Gonadotro Anti beta3 AR Human, Poly MOUSE ANTI HUMAN LUTEINIZ Chorionic Gonadotropin (C Luteinizing Hormone Relea Uroguanylin (circulating Isopeptidase T (long form Parathyroid Hormone Relat Luteinizing Hormone Relea

Related Pathways

paperclip

#30529793   // Save this To Up

Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.

To compare the Follicular Output Rate (FORT) between corifollitropin alfa (CFA) and recombinant follicle-stimulating hormone (rFSH) during controlled ovarian stimulation (COS).

2495 related Products with: Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.

Human Follicle-Stimulatio Rabbit Anti-Follicle Stim Rat follicle-stimulating Follicle Stimulating Horm Mouse Anti-Follicle Stimu Mouse Anti-Human Follicle Parathyroid Hormone Relat Human Thyroid Stimulating Growth Hormone, chicken r Macrophage Colony Stimula Recombinant human Growth Recombinant Human PKC the

Related Pathways

paperclip

#30406448   // Save this To Up

Could polymorphisms of some hormonal receptor genes, involved in folliculogenesis help in predicting patient response to controlled ovarian stimulation?

The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in selected genes, responsible for hormonal regulation of folliculogenesis, are associated with response to controlled ovarian hyperstimulation (COH) and clinical characteristics of women enrolled in in vitro fertilization (IVF) programs.

2140 related Products with: Could polymorphisms of some hormonal receptor genes, involved in folliculogenesis help in predicting patient response to controlled ovarian stimulation?

Goat Anti-Human EP4 prost (BCIP Toluidine)5 Bromo 4 Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Cell Meter™ Fluorimetri Mouse Anti-Human Interleu Nuclear Membrane Receptor Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Goat Anti- TACR2 Neurokin Rabbit Anti-Insulin Recep Ovarian cancer tissue arr

Related Pathways

paperclip

#30219283   // Save this To Up

Conventional versus minimal ovarian stimulation: an intra-patient comparison of ovarian response in poor-responder women according to Bologna Criteria.

Is minimal ovarian stimulation (MOS) as effective as conventional ovarian stimulation (COS) in ovarian response and embryo quality in the same 46 poor-responder patients according to the Bologna criteria?

1414 related Products with: Conventional versus minimal ovarian stimulation: an intra-patient comparison of ovarian response in poor-responder women according to Bologna Criteria.

Ovarian cancer tissue arr Ovary disease spectrum (o Ovarian cancer tissue arr Ovarian disease spectrum FIV Core Ag, recombinant CA125, Ovarian Cancer An Ovarian cancer tissue arr FDA Standard Frozen Tissu Human Ovarian Cancer Anti Rabbit Anti-Human Toll In Oral squamous cell cancer CA125, Ovarian Cancer An

Related Pathways

paperclip

#29738181   // Save this To Up

[Repeated superovulation induction after failure in previous IVF-ET cycles with the ultra-long protocol: Analysis of outcomes of clinical pregnancy].

To analyze the clinical outcomes of repeated superovulation induction in patients with adenomyosis or moderate to severe pelvic endometriosis after failure in previous IVF-ET cycles with the ultra-long protocol.

2972 related Products with: [Repeated superovulation induction after failure in previous IVF-ET cycles with the ultra-long protocol: Analysis of outcomes of clinical pregnancy].

Multiple organ tumor tiss Rectum cancer test tissue Prostate cancer tissue ar Liver carcinoma and norma Breast cancer test tissue Multiple malignant melano Rectum cancer tissue arra Colon cancer and normal t (S)-N-[2-[6-Allyloxy-5-br Colon carcinoma antibody Cervix cancer test tissue Ovarian cancer tissue arr

Related Pathways